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Increasing Burden of Melanoma in the United States
Eleni Linos1,2, Susan M. Swetter2,3,4, Myles G. Cockburn5, Graham A. Colditz6 and Christina A. Clarke1,4
It is controversial whether worldwide increases in melanoma incidence represent a true epidemic. Dramatic
increases in incidence in the setting of relatively stable mortality trends have also been attributed to expanded
skin screening and detection of biologically indolent tumors with low metastatic potential. To better understand
how melanoma incidence trends varied by severity at diagnosis and factors relevant to screening access, we
assessed recent United States incidence and mortality trends by histologic type, tumor thickness, and area-level
socioeconomic status (SES). We obtained population-based data regarding diagnoses of invasive melanoma
among non-Hispanic whites from nearly 291 million person-years of observation by the Surveillance
Epidemiology and End Results (SEER) program (1992–2004). Age-adjusted incidence and mortality rates were
calculated for SEER and a subset (California) for which small-area SES measure was available. Overall, melanoma
incidence increased at 3.1% (Po0.001) per year. Statistically significant rises occurred for tumors of all histologic
subtypes and thicknesses, including those44mm. Melanoma incidence rates doubled in all SES groups over a
10-year period whereas melanoma mortality rates did not increase significantly. We conclude that screening-
associated diagnosis of thinner melanomas cannot explain the increasing rates of thicker melanomas among
low SES populations with poorer access to screening.
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INTRODUCTION
Malignant melanoma is one of the fastest growing cancers
worldwide; studies from Europe (Mansson-Brahme et al.,
2002; de Vries and Coebergh, 2004; Lasithiotakis et al.,
2006; Stang et al., 2006), Singapore (Koh et al., 2003) Canada
(Ulmer et al., 2003), and the United States (Dennis, 1999;
Hall et al., 1999; Geller et al., 2002) suggest consistent and
dramatic increases in incidence since the 1950s. Yet the
underlying causes of these observed trends are widely
debated (Swerlick and Chen, 1996, 1997; Lamberg, 2002;
Florez and Cruces, 2004), with some authors attributing the
rapid rises to environmental risk factors and sun exposure
behavior (Diffey, 2004), and others maintaining they result
from expanded screening, biopsy (Welch et al., 2005), and
reporting of lower-risk melanomas to cancer registries
(Swerlick and Chen, 1996, 1997; Hall et al., 2003), notions
supported by relatively stable trends in melanoma mortality
for most groups. Promotion of skin screening programs (that
is, population-based screening, skin self-examination prac-
tices, and routine, opportunistic physician exams) may inflate
the numbers of cases, particularly those diagnosed at early
stage in the initial phases of program implementation, but
may also preferentially detect slow growing or clinically
insignificant disease. Therefore, to quantify the true burden of
clinically relevant disease, incidence patterns of thicker
melanomas may be more informative than those for all
melanomas combined.
There are several reasons that examining melanoma trends
according to socioeconomic status (SES) may be informative.
Socioeconomic status may be associated with both knowl-
edge about melanoma, as well as access to physician skin
screening, and low SES correlates with poorer health-care
access in the United States (Saraiya et al., 2004; Weissman
and Schneider, 2005). In the United States, patients from
higher SES groups are more likely to be diagnosed with
melanoma, but patients from lower SES groups, and those
with no or substandard health insurance are more likely to
have an advanced stage at diagnosis and to die from
melanoma (Roetzheim et al., 1999; Ortiz et al., 2005; Pollitt
et al., 2008). Therefore, a detailed assessment of time trends
in melanoma incidence and mortality among lower SES
groups can be informative about the underlying changes in
cancer rates among a potentially more poorly screened
population with more severe disease. Because information on
SES is generally not collected for individual patients by
cancer registries, assessments of melanoma trends by SES,
and tumor thickness have not been published, to our knowl-
edge. Moreover, prior analyses of melanoma incidence
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trends have assessed trends for all persons of white race,
regardless of ethnicity; however, this classification includes
two distinct groups: non-Hispanic whites who account for
over 90% of cutaneous melanoma cases in the United States,
and Hispanic whites in whom melanoma rates are very low,
but increasing (Cockburn et al., 2006). It is unclear to what
extent this mixing of two groups with heterogeneous
melanoma risks have biased prior estimations of melanoma
rate trends.
The primary aim of this analysis was to update our
understanding of melanoma trends in recent years, with
specific attention to their support of the notion of a possible
epidemic. Using data from the national Surveillance,
Epidemiology, and End Results (SEER) Program, we analyzed
incidence and mortality rates for invasive melanoma among
non-Hispanic whites according to tumor thickness and
histologic type, as well as by area SES in a subset of SEER
data.
RESULTS
In 2004, 7046 new cases of malignant melanoma were
reported in the 13 SEER registry areas of the United States.
The vast majority of cases occurred among non-Hispanic
whites (N¼6569, 93%), whereas 3% occurred in Hispanic
whites, 1% in Asians and Pacific islanders, and less than 1%
in blacks and American Indians, respectively. Melanoma
affected both sexes with a male: female ratio of 3:2. Data on
tumor thickness were available for 85% of cancer patients; of
these, most were p1mm (69%) with other thickness
distributions as follows: 17% 1.01–2mm, 9% 2.01–4mm
and 5% 44mm.
Incidence and mortality trends among non-Hispanic whites
1992–2004
A total of 70,596 new cases of malignant melanoma
were diagnosed over the study period, which included
290,913,376 person-years of observation. Incidence rates of
malignant melanoma increased significantly since 1992
(Figure 1), with an overall 45% increase and estimated
3.1% annual percent change (APC; Po0.001). In 1992, the
incidence rate was 18.2 (95% confidence interval, CI:
17.7–18.8) per 100,000 whereas in 2004 it was 26.3 (95%
CI: 25.7–27.0) per 100,000. Incidence rates varied more than
10-fold according to age and gender groups. Among those
younger than 65 years, incidence rates were 18.8 cases per
100,000 men and 17.9 cases per 100,000 women. Among
men 65 years and older, 73.2 (95% CI: 68.4–78.4) new cases
per 100,000 were diagnosed in 1992, giving this group both
the highest absolute rate as well as the fastest growing
incidence rate (APC 4.50% per year), which reached 126.1
(95% CI: 120.2–132.4) per 100,000 in 2004.
Among non-Hispanic whites, 37.5% had superficial
spreading melanoma (N¼26,461), 7.4% had nodular mela-
noma (N¼5264), 7.3% had lentigo maligna melanoma
(N¼5141), 0.9% had acral lentiginous melanoma
(N¼616) and 4.4% had other subtypes (N¼ 3137). Over
40% of cases (N¼29,977) were missing histologic subtype
classification (for example, not otherwise specified). Regard-
less, no significant differences in the proportions of tumors
according to histologic subtype were evident over time. The
incidence rates per 100,000 of superficial spreading mela-
noma increased from 7.6 in 1992 to 8.5 in 2004; incidence
rates of nodular melanoma increased from 1.5 in 1992 to 1.7
in 2004, and rates of lentigo maligna melanoma rose from 1.2
to 2.0 over the same period.
Overall mortality from malignant melanoma increased at
an annual rate of 0.4% from 1990 to 2004 (Table 1). For men
and women over 65 years of age, mortality increased by
1.7% annually, reaching 14.3 deaths per 100,000 in 2004.
Men over 65 years had the fastest increase in mortality over
this period (APC 1.9%) reaching 22.7 deaths per 100,000 in
2004. Mortality rates decreased among persons younger than
65 years at diagnosis (APC—0.9%) remaining low at 1–2
deaths per 100,000 (Figure 2).
Incidence trends by tumor thickness
Melanoma incidence rates increased across all groups of
tumor thickness. The overall annual increase in incidence
ranged from 0.43 to 6.88% per year across the four groups of
tumor thickness (Table 2). The overall incidence of tumors
44mm thick increased by 3.86% each year (4.10% men,
3.30% women). The annual percent increase in incidence
was highest for men over 65 years old, 4.50% overall and per
thickness categories: 6.88% for melanomas p1mm, 4.76%
for 1.01–2mm, 3.86% for 2.01–4mm, and 5.67% for44mm
tumors.
Because complete reporting of tumor thickness improved
over the study period, we quantified the potential impact of
this change on observed trends. The proportion of melanoma
cases missing thickness information dropped from 20% in
1992–1996 to 12% in 2000–2004, a reduction of approxi-
mately 40%. To understand the impact of this change, we
reallocated 40% of the missing tumors in 1992–1996 to each
of the groups with known thickness (Table 3) in several
iterations: (1) proportionally to all thickness categories, which
assumes that reporting improved uniformly across all thick-
ness levels; (2) disproportionately (twice as many cases to
the 2.01–4mm and 4mmþ groups), which assumes that
reporting improved selectively among thicker tumors; and
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Figure 1. Age adjusted incidence of malignant melanoma per 100,000
according to age and sex 1992–2004. Note: Y axis is logarithmic scale.
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(3) disproportionately to the thinnest tumor category
(p1mm), which assumes that reporting improved selectively
among thin tumors. We considered the latter iteration to be
the most realistic, because most of the cases with missing
thickness information were among high SES groups, which
include a higher proportion of thinner tumors. In all
iterations, incidence trends remained statistically significant
across all thickness levels (Table 3). Therefore, we concluded
that trends in missing thickness level did not change the
interpretation of our findings.
Trends according to socioeconomic status in California
A total of 29,792 cases of cutaneous melanoma in the state of
California were included in the SES analyses. Persons living
in areas of highest SES were at higher absolute risk of all
melanomas. As shown in Figure 3, increasing trends in
incidence rates over time were observed across all SES groups
and tumor thickness levels. For each of the SES groups and
tumor thickness classifications, there was at least a twofold
increase in rates comparing the period of 1988–1992 to
1998–2002. Persons living in low SES areas experienced the
highest increases in melanoma incidence, and among the
lowest SES group, the steepest rises in melanoma incidence
were observed for thicker tumors (2.01–4 and X4.01mm;
Table 4). Mortality rates among different socioeconomic
groups did not change significantly between the two time
periods (data not shown).
DISCUSSION
Our analysis of almost 300 million person-years and over
70,000 new cases of malignant melanoma, the largest such
assessment to date, suggests a continued rise in new cases of
malignant melanoma in the United States. These findings
update through 2004 prior reports indicating persistent rises
in incidence from the 1960s in the United States (Geller et al.,
2002; Ries et al., 2002) and are consistent with mounting
evidence of similar trends worldwide (Mansson-Brahme
et al., 2002; de Vries et al., 2003a, b; Ulmer et al., 2003;
Koh et al., 2003; de Vries and Coebergh, 2004; Lasithiotakis
et al., 2006; Stang et al., 2006). Unlike prior large SEER-based
analyses, we were able to assess trends jointly by tumor
thickness and SES, which allowed for more precise char-
acterization of thick melanoma trends in populations likely to
be unscreened or with limited access to physician screening.
We observed that melanoma incidence increased for both
men and women across all categories of tumor thickness,
including a significant 3.86% annual increase among the
Table 1. Deaths from malignant melanoma, age adjusted (2000 US standard) mortality rate among non-Hispanic
whites for 2004: annual percent change in mortality rates 1990–2004
0–64 years 65+ years 0–85+ years
Men
No. of deaths from melanoma in 2004 2,168 2,799 4,967
Mortality rate per 100,000 in 2004 2.2 (2.1–2.3) 22.7 (21.9–23.6) 4.8 (4.6–4.9)
Trend APC (%), P-value 1.0* 1.9* 0.6*
Women
No. of deaths from melanoma in 2004 1,156 1,531 2,687
Mortality rate per 100,000 in 2004 1.2 (1.1–1.2) 8.5 (8.0–8.9) 2.1 (2.1–2.2)
Trend APC (%), P-value 0.9* 0.8* 0.1
All
No. of deaths from melanoma in 2004 3,324 4,330 7,654
Mortality rate per 100,000 in 2004 1.7 (1.6–1.7) 14.3 (13.8–14.7) 3.3 (3.2–3.3)
Trend APC (%), P-value 0.9* 1.7* 0.4*
APC, annual percent change in mortality rate.
*Statistically significant difference Po0.05.
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Figure 2. Age adjusted mortality rates from melanoma per 100,000
according to age and sex 1990–2004.
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thickest tumors (44mm). Interestingly, this increase did not
correlate with a disproportionate increase in nodular
melanomas, which are characterized by rapid growth and
may elude early detection. As with prior reports (Geller et al.,
2002), incidence increases were most dramatic for men aged
65 and older. These observations persisted in analyses
accounting for improvements in reporting of tumor thickness.
When patients were divided according to neighborhood-level
SES, increases were noted in all groups, especially those in
the lowest two quintiles. Importantly, the lowest SES group
demonstrated the steepest rise in the incidence of thick
tumors 44mm.
Mortality from melanoma continued to increase,
especially among men aged 65 and older (approximately
2% increase annually), consistent with previous reports
(Geller et al., 2002; Ries et al., 2002) although mortality
rates decreased for men and women younger than 65. For
all cancers, age is one of the strongest risk factors,
presumably because of accumulating DNA damage over
time. Melanoma in the elderly may have a different
biology and altered host immune response, both of
which could contribute to increased incidence and mortality
(Balch et al., 2001b). Regardless, the pattern of dramatic
increases in melanoma among persons over 65 in the face
of decreasing mortality among younger men and women is
notable.
Some have argued that the rapid rises in melanoma
incidence are indicative of a true epidemic on the basis of
greater ultraviolet radiation-induced carcinogenesis, whereas
others insist that the apparent trends are an artifact of
improved surveillance, diagnostic scrutiny (Welch et al.,
2005), and regular screening (Swerlick and Chen, 1996)
leading to increased diagnosis of thinner tumors with lower
or no metastatic potential. Our findings inform this debate by
showing persistent increases among more fatal, thick
(44mm) tumors and contest the argument that rising
Table 2. Age adjusted (2000 US standard) incidence of malignant melanoma among non-Hispanic whites and 95%
confidence intervals for 2004 according to age and tumor thickness, SEER 1992–2004
Men Women
Tumor thickness
No. of cases
(%)
Age-adjusted incidence
rate per 100,000 in 2004
Trend APC (%)
1992–2004
No. of cases
(%)
Age-adjusted incidence
rate per 100,000 in 2004
Trend APC (%)
1992–2004
Age
0–85+ years
p1mm 2,306 (61%) 19.7 (18.9–20.6) 4.84* 1,869 (66%) 14.9 (14.3–15.6) 4.68*
1.01–2mm 499 (13%) 4.3 (3.9–4.7) 2.39* 389 (14%) 3.0 (2.7–3.3) 3.16*
2.01–4mm 318 (8%) 2.8 (2.5–3.1) 2.54* 153 (5%) 1.1 (0.9–1.3) 1.80
X4.01mm 200 (5%) 1.7 (1.5–2.0) 4.10* 103 (4%) 0.7 (0.6–0.9) 3.30*
Unknown 435 (12%) 3.8 (3.4–4.1) 2.88* 297 (11%) 2.3 (2.0–2.6) 2.48*
All1 3758 32.3 (31.3–33.4) 2.96* 2811 22.0 (21.2–22.9) 3.21*
0–64 years
p1mm 1,346 (64%) 12.1 (11.4–12.8) 3.42* 1,344 (72%) 12.8 (12.2–13.6) 4.33*
1.01–2mm 273 (13%) 2.5 (2.2–2.8) 0.44 243 (13%) 2.3 (2.0–2.6) 2.91*
2.01–4mm 145 (7%) 1.3 (1.1–1.5) 0.84 75 (4%) 0.7 (0.5–0.9) 0.42
X4.01mm 100 (5%) 0.9 (0.7–1.1) 1.96 39 (2%) 0.4 (0.3–0.5) 1.40
Unknown 229 (11%) 2.1 (1.8–2.3) 3.66* 177 (9%) 1.7 (1.4–2.0) 2.65*
All1 2,093 18.8 (18.0–19.6) 1.68* 1,878 17.9 (17.1–18.7) 2.97*
65+ years
p1mm 960 (58%) 72.6 (68.1–77.4) 6.88* 525 (56%) 29.4 (26.9–32.1) 5.88*
1.01–2mm 226 (14%) 17.1 (15.0–19.5) 4.76* 146 (16%) 7.7 (6.4–9.0) 3.71*
2.01–4mm 173 (6%) 13.2 (11.3–15.3) 3.86* 78 (8%) 4.1 (3.2–5.1) 3.73*
X4.01mm 100 (10%) 7.6 (6.2–9.2) 5.67* 64 (7%) 3.2 (2.5–4.1) 5.10*
Unknown 206 (12%) 15.6 (13.6–17.9) 2.14* 120 (13%) 6.4 (5.3–7.7) 2.17*
All1 1,665 126.1 (120.2–132.4) 4.50* 933 50.8 (47.5–54.2) 3.84*
APC, annual percent change in incidence rate.
*Statistically significant difference Po0.05.
1Includes all malignant melanoma, including those for which thickness was not recorded.
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incidence rates are solely attributable to increased diagnosis
of thinner tumors.
Increasing incidence of thicker melanomas has been
reported in earlier population-based studies (Dennis, 1999;
Geller et al., 2002) but was not noted in recent regional
studies from France (Lipsker et al., 2007) and Germany
(Lasithiotakis et al., 2006). This discrepancy may reflect
variations in patterns of disease presentation or study
methodology differences including smaller sample sizes in
the European studies. Above and beyond diagnostic surveil-
lance, it is possible that reported trends in melanoma have
been influenced by patterns of melanoma reporting to cancer
registries. Although it is likely that reporting of thin tumors did
improve over time as physicians realized their reporting
responsibilities, we did not find evidence of selective
overreporting of thin tumors among persons of higher SES
groups. Thus, it is unlikely that reporting patterns explain the
SES-specific incidence patterns observed here.
Routine screening for skin cancer is currently recom-
mended by the American Cancer Society (Smith et al., 2007).
However, the proportion of non-Hispanic white adults who
reported ever having a physician skin examination in
National Health Interview Surveys conducted in 1992,
1998, and 2000 ranges from only 14 to 21%, and physician
screening is rare among those without health insurance
(Saraiya et al., 2004). Our data showing increases in
melanoma incidence across all SES groups are consistent
with previous reports of melanoma increases by census tract
poverty level from 1975 to 1999 (Singh et al., 2003).
However, our findings of increasing incidence in low SES
groups, who may have reduced access to health prevention
education and practices, suggest a true increase in melanoma
burden independent of screening access.
Our observations of modest increases in mortality rates in
the presence of dramatic increases in incidence are curious,
and are probably not attributable to improvements in
survival, treatment, or early detection alone. Median survival
for late-stage melanoma in the United States has not changed
appreciably over the past 30 years (Barth et al., 1995), nor
have there been any major innovations in melanoma
Table 3. Sensitivity analysis assessing the impact of improved reporting of tumor thickness on melanoma trends
according to tumor thickness
Total 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
% Missing before correction 15 23 21 20 17 16 15 15 14 13 13 12 12 11
% Missing after correction 12 13 11 11 9 8 15 15 14 13 13 12 12 11
Annual percent change
1. Underreporting in
all thicknesses
2. Selective underreporting
of thick tumors
3. Selective underreporting
of thin tumors
1mm 3.85* 4.14* 3.40*
1–2mm 1.41* 1.76* 2.68*
2–4mm 1.54* 0.25 2.22*
4mm+ 3.37 1.85* 3.86*
Missing thickness 3.14 3.44 3.08*
Overall 2.97* 3.08* 2.16
*Statistically significant difference Po0.05.
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Figure 3. Age adjusted incidence of melanoma according to levels of SES (1–5) and by tumor thickness. Note: Y axis in all graphs is log incidence.
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Table 4. Trends over time according to SES and tumor thickness: incidence rate ratio1 comparing period 2
(1998–2002) to period 1 (1988–1992)
Women Men All
Thickness SES2 0–64 years 65+ years 0–64 years 65+ years 0–64 years 65+ years
p1mm
1 2.24 2.01 2.22 2.70 2.26 2.42
2 1.88 1.97 1.98 2.38 1.93 2.19
3 1.96 1.96 1.89 2.18 1.94 2.13
4 2.08 2.13 1.76 2.13 1.93 2.17
5 1.67 1.84 1.73 1.97 1.69 1.95
1.01–2mm
1 5.25 7.00 4.00 3.97 4.4 4.89
2 3.8 3.89 3.83 8.11 3.5 5.56
3 3.14 3.58 3.09 4.68 3.11 4.24
4 2.36 4.14 2.54 4.06 2.42 4.16
5 2.55 2.44 2.47 3.28 2.5 2.98
2.01–4mm
1 — 12.25 3.33 6.52 5.00 8.3
2 4.00 8.83 5.67 9.75 4.33 9.88
3 2.67 4.45 2.83 4.88 3.00 5.27
4 2.50 2.57 2.25 4.39 2.33 3.48
5 2.25 3.33 2.29 3.05 2.00 3.23
X4.01mm
1 4.0 4.0 13.0 5.48 8.0 5.38
2 — 4.5 3.33 11.29 4.0 6.71
3 4.0 4.0 3.33 6.69 3.5 5.44
4 2.0 4.13 2.67 5.4 3.0 5.17
5 2.0 4.33 2.67 4.36 2.0 4.31
Unknown3
1 0.45 0.52 0.69 0.85 0.57 0.68
2 0.45 0.58 0.46 0.67 0.45 0.61
3 0.45 0.66 0.42 0.68 0.43 0.64
4 0.40 0.53 0.45 0.68 0.43 0.61
5 0.40 0.53 0.39 0.57 0.39 0.54
All
1 1.68 1.68 1.74 2.07 1.70 1.93
2 1.49 1.71 1.51 1.98 1.50 1.87
3 1.54 1.67 1.43 1.81 1.49 1.81
4 1.50 1.67 1.37 1.88 1.42 1.83
5 1.30 1.55 1.32 1.63 1.31 1.63
SES, socioeconomic status.
—used when unable to calculate ratio as denominator is equal to zero.
1Incidence rate ratio was calculated as the number of new cases of melanoma per 100,000 that occurred during period 1 (1998–2002) divided by the number
of new cases of melanoma per 100,000 in period 2 (1988–1992).
2Socioeconomic status was divided into 5 quintiles based on an index of neighborhood SES based on characteristics of the census tract of patient residence at
the time of diagnosis. SES1 (lowest), SES 5 (highest) (Yost et al., 2001).
3The percentage of cases with missing thickness across SES groups 1 through 5 is: 32, 28, 25, 22, and 21% respectively.
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treatment (Korn et al., 2008). Although the influence of a
stage distribution shift toward thinner, more curable tumors
has occurred in recent decades (Geller et al., 2007), the
incidence of thicker melanoma has not declined (Jemal et al.,
2001) as supported by our findings of persistent increases in
melanomas of all thicknesses over the study period.
This study provides a comprehensive analysis of the most
recent SEER data covering a large segment of the US
population. Additional strengths include a more specific
classification of ethnicity of non-Hispanic whites, providing
precise estimates of risk of melanoma among those at highest
risk. Moreover, calculation of SES-specific incidence trends
allowed us to examine trends of thicker tumors in a
population with poorer access to screening. Complete SES
data were available for the state of California; however, this
reflected relative SES of the patient’s neighborhood at the
time of diagnosis, and therefore may be misclassified with
respect to socioeconomic characteristics measured at the
individual level or for time periods before diagnosis. SES-
specific data were not available outside the state of
California.
Incomplete reporting of certain cancer registry data items,
including histologic subtype and thickness, may have biased
the ultimate representativeness of our final study cohort. This
issue underscores the dependence of accurate melanoma
surveillance on both the quality and completeness of
melanoma reporting to cancer registries by diagnosing
hospitals and physicians (Hall et al., 2003). Underreporting
(Koh et al., 1992; Zippin et al., 1995; Cockburn et al., 2008,
in press) and delayed reporting (Clegg et al., 2002) of
melanoma to cancer registries have been documented and
indicate that even the best assessments of melanoma
incidence patterns likely represent underestimates.
We do not believe that improvements in the reporting of
thickness information over time could fully explain our
observations of increasing incidence trends across all
thickness categories, as demonstrated in our sensitivity
analyses described above. Furthermore, missing thickness
was not associated with patient age, sex, or suggesting that
thickness data are largely missing at random.
The absolute magnitude of melanoma incidence in older
white men warrants greater public health attention, as these
data suggest a contemporary incidence rate exceeding 125
cases per 100,000 men aged 65 and older. This is
proportional to the incidence of non-Hodgkin’s lymphoma
in the same population, making malignant melanoma the fifth
most common cancer in older white men following prostate,
lung, colorectal, and bladder cancer. If melanoma is truly
increasing in all thickness categories and across socio-
economic levels, it will soon become a major concern for
an increasingly aging population and their health-care
providers. Secondary prevention through early detection of
melanoma is especially important in reducing mortality in
high-risk groups (Geller et al., 2006), including those of
lowest SES who demonstrated the sharpest rises in thick
melanoma incidence in the California data. Our analysis also
highlights the need for continued, detailed surveillance of
melanoma occurrence, which in turn, underscores the
importance of complete and accurate reporting of all
melanoma cases by hospitals and private physicians.
MATERIALS AND METHODS
Population
Data on newly diagnosed cases of malignant melanoma were
obtained from the National Cancer Institute’s SEER program (SEER).
Information on mortality from melanoma was obtained from the
National Center for Health Statistics. SEER data are collected by 13
population-based cancer registries including Atlanta, Connecticut,
Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland,
Seattle-Puget Sound, Utah, Los Angeles and San Jose-Monterey, rural
Georgia and the Alaska Native Tumor Registry. The non-Hispanic
white population covered by SEER is somewhat more urban but
otherwise generally representative of the overall US population.
Because of the disparate incidence of melanoma in fair-skinned
populations, previous studies on melanoma trends in the United
States have restricted analyses to individuals of white ethnicity (Hall
et al., 1999; Geller et al., 2002). For more accurate assessment, we
limited our analyses to non-Hispanic whites who account for over
90% of melanoma cases in the United States. Because of our
particular interest in melanoma trends according to tumor thickness,
we further restricted our analysis to the time period for which data on
these variables were available in the SEER database; from 1992 to
2004 (the most recent year available for which Veterans Adminis-
tration reporting to SEER was complete). We obtained data regarding
all incident cases of invasive cutaneous melanoma (International
Classification of Diseases for Oncology topography codes C44.0
through C44.9) including year at diagnosis, tumor thickness,
histology, patient age, race, and sex. All patient and tumor
information was abstracted and coded directly from the medical
record or death certificate by trained cancer registry personnel.
Assignment of patient Hispanic race/ethnicity was augmented by
Hispanic surname lists. International Classification of Diseases for
Oncology-3 classification of histology was used to examine trends
in superficial spreading melanoma (8743), nodular melanoma
(8721), lentigo maligna melanoma (8742), acral lentiginous mela-
noma (8744), melanoma not otherwise specified (8720) and other
histologic types (other; 8723, 8730, 8740, 8745, 8761, 8770–8773,
and 8780). Tumor thickness was classified according to 2002
American Joint Committee on Cancer tumor (T) categories as o1,
1.01–2, 2.01–4 or 44mm (Balch et al., 2001a). On average, tumor
thickness was not recorded in 15.1% of the SEER melanoma patients.
Patients with missing thickness information did not differ signi-
ficantly from patients with known melanoma thickness by age at
diagnosis or gender, although missing thickness information was
more common among higher SES groups. The proportion of
melanomas with missing thickness information declined over time.
We therefore performed sensitivity analyses to assess the impact on
our results of improved reporting of thickness over time.
Socioeconomic status index
Three of the SEER member registries, together comprising the
statewide California Cancer Registry, developed a measure of
neighborhood SES based on characteristics of the census tract of
patient residence at the time of diagnosis. This small-area measure
has been used previously to predict cancer and other health
outcomes (Yost et al., 2001; Clarke et al., 2005). This index
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incorporates information regarding education, median household
income, proportion living 200% below poverty level, proportion of
blue-collar workers, proportion older than 16 years and unem-
ployed, median rent and median house value using principal
components analysis as described by Yost et al. (2001). The index
was divided into quintiles (1¼ lowest, 5¼ highest). Complete
information on census tract SES index was available for all
individuals in this analysis. This was assigned randomly within
county of residence at diagnosis for patients with unknown census
tract of residence. Because census tract-level population denomi-
nators are available from the US Census Bureau for decennial census
years only, we examined SES-specific trends for the 5-year periods
surrounding decennial census years, (for example, 1988–1992 and
1998–2002).
Statistical analysis
SEER*Stat software (SEER*Stat) was used to calculate annual
melanoma incidence and mortality rates for each year between
1992 and 2004, reported as cases or deaths per 100,000 people, and
age-adjusted to the 2000 US population standard. Standard errors,
95% confidence intervals, and all tests of statistical significance are
two-sided, P-value¼ 0.05. Incidence trends for each classification
of tumor thickness were examined using estimated APCs from 1992
to 2004, calculated by fitting a least squares regression line to the
natural logarithm of the rates, using calendar year as the dependent
variable. Because only two time periods were available for SES-
specific trends, we calculated SES-specific incidence rate ratios to
comparing period 2 (1998–2002) to period 1 (1988–1992).
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